Attach importance to the diagnosis of cerebral amyloid angiopathy and cerebral amyloid angiopathy related inflammation
10.3760/cma.j.cn113694-20250317-00140
- VernacularTitle:重视脑淀粉样血管病与脑淀粉样血管病相关炎症的诊断
- Author:
Yifan LI
1
;
Zhengqi LU
1
Author Information
1. 中山大学附属第三医院神经内科，广州 510630
- Publication Type:Journal Article
- Keywords:
Amyloid;
Cerebral amyloid angiopathy;
Cerebral amyloid angiopathy related inflammation;
Amyloid related imaging abnormalities
- From:
Chinese Journal of Neurology
2025;58(8):811-815
- CountryChina
- Language:Chinese
-
Abstract:
Amyloid-β (Aβ) is a common protein in organisms. It participates in important physiological functions such as bacterial biofilms and affects melatonin production, and misfolded or excessive Aβ is a potential pathogenic factor that can cause amyloidosis in organs or systems. Cerebral amyloid angiopathy (CAA), as a common cerebral small vessel disease, is characterized by abnormal deposition of 1-40 peptides of Aβ protein, which will not only damage the normal structure of cerebral vessels, but also affect the normal structure and function of neurons, increasing the risk of cerebral hemorrhage. In addition, Aβ protein can further induce autoimmune response on the basis of CAA pathology, leading to a variety of pathological changes of CAA related inflammation (CAA-ri). Clinically, Alzheimer′s disease patients often coexist with CAA. In recent years, targeted Aβ protein antibody therapy for Alzheimer′s disease patients has been emerging, including monoclonal antibody therapy. A few patients will have amyloid related imaging abnormalities. These therapies have significant effects in reducing amyloid levels and improving patients′ clinical symptoms, but their treatment efficiency and side effects are still major challenges facing current research. The role of amyloid protein in the clinical early recognition of CAA and CAA-ri and the decision-making of early intervention were discussed in this article.
